Category Archives: Deals

CRO M&As Show No Sign of Slowing Down

By Lisa Henderson. With all of the activity in CRO M&As the past three years, it’s slightly amazing that it continues — and that analysts don’t see it slowing down. In fact, investment analysts speaking to the Partnerships in Clinical Trials event this month believe that from a Wall Street perspective, the publicly-traded CROs are […]
Also posted in Guest Blog, Strategy | Tagged , , , , | Leave a comment

M&As and IPOs Shake Up CMO Industry

The CMO industry is undergoing a wave of ownership changes, including acquisitions, divestitures, and initial public offerings (IPOs). Ownership changes can lead to significant changes in a company’s strategy, focus, and prospects, so it is important for bio/pharmaceutical companies to review the implications of a key supplier’s change in ownership, writes Jim Miller. Recently announced […]
Also posted in Manufacturing | Tagged , , , | Leave a comment

Weak IP Protection Threatens Asia-Pac Biotech Boom

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital  investments in biotechnology. According to research and consulting firm GlobalData, healthcare private equity investment in APAC increased by 125.8% between 2011 and 2013,  whereas deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 […]
Also posted in Emerging Markets, Global, IP | Tagged , , , | Leave a comment

Venn Life Sciences Puts LabSkin in the Game

Just think what Frankenstein could do with this product. It looks like skin, feels like skin, but it’s not skin. It’s LabSkin, a facsimile, being manufactured by a clinical research group Venn Life Sciences. Demand for replacement technologies stemmed from the European Union ban on selling cosmetics tested on animals in March 2013, proving where […]
Also posted in R&D, Technology | Tagged , , , | Leave a comment

Actavis to Acquire Forest Labs for $25 Billion

Actavis and Forest Laboratories have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share, Actavis announced in a press release. The transaction will combine the two high-growth specialty pharmaceutical companies, with combined annual revenues of more […]
Posted in Deals | Tagged , , , | Leave a comment
  • Categories

  • Meta